Our Vision

Our vision is for AXM Pharma to become a premier China-based US GMP pharmaceutical manufacturer and distributor targeting and penetrating the markets of China, Hong Kong, Taiwan, Korea, The Philippines, Indonesia, Malaysia, Singapore and Thailand. The growth plan includes expanding the breadth of the existing product line with new pharmaceutical products licensed from North America and Europe. AXM Pharma intends to locate its new US GMP plant in a special economic zone in Shenyang. We believe this growth strategy, coupled with the existing facility’s history, will provide increased revenues, greater gross profit margins and higher net profits. AXM Pharma will augment this strategy by providing strategic planning, North American-based management and financial controls, North American product licensing expertise, international market development activities, North American corporate governance, and US GMP standardization compliance advice. After the Company achieves US GMP standardization, the Company intends to expand its marketing and sales reach to cover exports to North America, Asia-Pacific, Africa and Europe. In addition, the Company will actively seek and engage, foreign ethical drug marketers that are searching for low cost manufacturers for their high demand medications.

Our Strategy

We will pursue this vision using four major initiatives:

• Construction of new facilities that meet US GMP standards;
• Continuation and expansion of existing successful manufacturing and regional marketing strategies in China and the Asia-Pacific region;
• Enhancement and enlargement of existing product line by licensing U.S. and European based high quality, high margin, ethical and Over The Counter (“OTC”) pharmaceuticals products for sale in Asia-Pacific; and
• Development of a unique family of OTC pharmaceutical and products for sale in North America.

These initiatives will be accomplished through the formation of strategic alliances with pharmaceutical organizations who have no presence in China and are willing to license the rights to manufacture and sell their products in China for an appropriately structured royalty schedule. A sizable number of such organizations exist, and it is our belief that these organizations will welcome the opportunity to partner and collaborate with an American managed company with proven capabilities in manufacturing (US GMP standards in 2004), marketing and sales of ethical pharmaceuticals in China.